NCT07074236 - Pharmacokinetics and Pharmacodynamics Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions

Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C

Interventions

DRUG

QLC7401 injection

QLC7401 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. QLC7401 injection was introduced by Qilu Pharmaceutical Co., Ltd. from Suzhou Ruibo Biotechnology Co., Ltd. QLC7401 injection was produced by Qilu Pharmaceutical Co., Ltd.

DRUG

RBD7022 injection

RBD7022 injection is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA to inhibit the translation of PCSK9 and reduce expression of PCSK9 protein further to lower the level of LDL-C. RBD7022 injection was produced by Suzhou Ruibo Biotechnology Co., Ltd.

Trial Locations (1)

Unknown

The Affiliated Hospital of Qingdao University., Qingdao

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY